Daily Archives

November 7, 2018

Home / November 7, 2018

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial

Source: JAMA
Abstract: Importance: Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for treating episodic migraine. Conclusions and Relevance: Among patients with episodic migraine in whom multiple medication classes had not previously failed, subcutaneous fremanezumab, compared with placebo, resulted in a statistically significant 1.3- to 1.5-day reduction in the mean number of monthly migraine days over a 12-week period.
Read more…

ICER Report Supports Cost Effectiveness of CGRP Inhibitors

Source: Institute for Clinical and Economic Review (ICER)
A recently released Institute for Clinical and Economic Review (ICER) evidence report assessing the comparative clinical effectiveness and value of three calcitonin gene-related peptide (CGRP) inhibitors for prevention of migraine attacks found that the price of the therapies aligns with the value to patients for whom other preventive treatments have failed.
Read the report…

Clinical Studies Show Impact of Migraine across Various Stages of Women’s Lives

Source: American Headache Society
At the American Headache Society (AHS)’s 60th Annual Scientific Meeting, leading migraine experts are presenting five clinical studies that deepen the understanding of the effects of episodic and chronic migraine on women’s lives throughout the years, including their personal relationships and family life. Of the 37 million Americans who suffer from migraine, 28 million are women. Research indicates women experience migraine differently than men, and their episodes of migraine often last longer.
Full story…

Migraine Prevention Drugs Demonstrate Net Health Benefit

Source: Institute for Clinical and Economic Review
The Institute for Clinical and Economic Review released a final evidence report on three calcitonin gene-related peptide (CGRP) inhibitors for prevention of migraine. Panel members voted that evidence was adequate to demonstrate a net health benefit of the CGRP inhibitors for individuals with chronic migraine and no other available treatment options.
Read Final Evidence Report and Report-at-a-Glance

1 2 3 4 5
Pain Medicine Journal
Access to this page is restricted to members only! Not a mamber? Join Now!

Ask Us Anything. Anytime.

📝 Fill in your details and we’ll get back to you in no time.

American Academy of Pain Medicine